|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
Suite 150
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
||
|
|
|
Item 5.03. |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
|
Item 5.07. |
Submission of Matters to a Vote of Security Holders.
|
Nominee
|
Votes
For
|
Votes
Withheld
|
Broker
Non-Votes
|
• Thomas Eastling
|
68,900,969
|
211,021
|
331,358
|
• Renate Parry, Ph.D.
|
69,107,060
|
4,930
|
331,358
|
• Rodney Nussbaum
|
69,107,047
|
4,943
|
331,358
|
Votes
For
|
Votes
Against
|
Abstentions
|
Broker
Non-Votes
|
69,101,285
|
7,487
|
3,218
|
331,358
|
Votes
For
|
Votes
Against
|
Abstentions
|
Broker
Non-Votes
|
69,435,580
|
7,601
|
167
|
0
|
Votes
For
|
Votes
Against
|
Abstentions
|
Broker
Non-Votes
|
68,971,890
|
136,936
|
3,164
|
331,358
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit
Number
|
Exhibit Title or Description
|
|
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Gyre Therapeutics, Inc.
|
||
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
GYRE THERAPEUTICS, INC.
|
||
Date: June 17, 2024
|
By:
|
/s/ Han Ying, Ph.D.
|
Name:
|
Han Ying, Ph.D.
|
|
Title:
|
Chief Executive Officer
|
/s/ Han Ying, Ph.D.
|
||
Han Ying, Ph.D.
|
||
Chief Executive Officer
|